NEW YORK, Dec. 2 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Markets for Asthma and COPD Drugs

http://www.reportlinker.com/p0166826/Global-Markets-for-Asthma-and-COPD-Drugs.html

Provides an in-depth analysis of the global market for medications that treat asthma and chronic obstructive pulmonary disease

Contains global market forecasts through 2014 for medications that treat asthma and chronic obstructive pulmonary disease

Discusses the major classes of drugs currently approved and available in the market including bronchodilators, anti-inflammatories and combination therapies

Includes information on industry structure along with company profiles

Describes the regulatory environment for production and competition factors that affect the industry.

Chapter- 1: INTRODUCTION -- Complimentary

STUDY GOALS AND OBJECTIVES 1

REASONS FOR DOING THE STUDY 1

SCOPE OF REPORT 1

METHODOLOGY 2

INTENDED AUDIENCE 2

INFORMATION SOURCES 2

ANALYST CREDENTIALS 3

RELATED BCC REPORTS 3

BCC ONLINE SERVICES 3

DISCLAIMER 4

Chapter-2: SUMMARY

CHAPTER TWO: SUMMARY 5

SUMMARY TABLE GLOBAL MARKET FOR ASTHMA AND COPD DRUGS, THROUGH 2014 ($ MILLIONS) 5

SUMMARY FIGURE GLOBAL MARKET FOR ASTHMA AND COPD DRUGS, 2007-2014 ($ MILLIONS) 6

Chapter-3: OVERVIEW

INTRODUCTION 7

ASTHMA 7

CHRONIC OBSTRUCTIVE PULMONARY DISEASE 7

MEDICATION TREATMENT 8

CLASSIFICATION OF ASTHMA AND COPD DRUGS 8

Bronchodilators 9

Anti-inflammatory Drugs 9

Combination Inhaled Corticosteroids and Long-acting Beta-2 Agonists (ICS/LABA) 10

TABLE 1 MARKETED ASTHMA AND COPD DRUG CLASSES 10

DRUG DELIVERY METHODS 11

Metered-dose Inhaler 11

Dry Powder Inhalers 12

Nebulizers 13

Oral and Injectable Drugs 13

DRUG DEVELOPMENT PROCESS 14

DISEASE-MODIFYING DRUGS--AN ELUSIVE QUEST 14

COMPLEX REGULATORY DRUG APPROVAL PROCESS 15

TECHNICAL ASPECTS IN THE DEVELOPMENT OF INHALED DRUGS 15

REGULATORY ISSUES 16

REMOVAL OF CFC-PROPELLED INHALERS 17

FDA DRUG SAFETY WARNINGS 17

INDUSTRY PLAYERS 18

MAJOR DRUG MANUFACTURERS 18

SPECIALTY PHARMACEUTICAL COMPANIES 18

SMALLER COMPANIES 19

COMPETITIVE FACTORS 20

SIGNIFICANT TRENDS 21

GLOBAL AGING POPULATION TO LEAD TO INCREASING ASTHMA AND COPD PREVALENCE 21

NEW DRUG LAUNCHES TO OFFER ENHANCED TREATMENT OPTIONS 21

PATENT EXPIRATIONS OF MAJOR DRUGS AND GENERIC DRUG LAUNCHES TO SLOW MARKET GROWTH 22

Chapter-4: DISEASE OVERVIEW

ASTHMA OVERVIEW 23

CLASSIFICATION OF ASTHMA 23

TABLE 2 CLASSIFICATION OF ASTHMA BY SYMPTOMS 23

CAUSES AND RISK FACTORS 24

DIAGNOSIS 24

DRUG CLASSES APPROVED IN THE TREATMENT OF ASTHMA AND COPD 25

TABLE 3 ASTHMA AND COPD DRUG CLASSES 25

BRONCHODILATORS 26

ANTI-INFLAMMATORY DRUGS 26

COMBINATION THERAPIES OF BRONCHODILATORS AND ANTI-INFLAMMATORY DRUGS 26

MEDICATION TREATMENT ALGORITHMS 27

FIRST LINE OF THERAPY 27

SECOND LINE OF THERAPY 27

CHRONIC OBSTRUCTIVE PULMONARY DISEASE 27

CLASSIFICATION OF COPD 28

TABLE 4 ASTHMA AND COPD DRUG CLASSES 28

CAUSES AND RISK FACTORS 28

DIAGNOSIS 29

MEDICATION TREATMENT ALGORITHMS 29

MEDICATION TREATMENT ALGORITHMS (CONTINUED) 30

Chapter-5: INDUSTRY STRUCTURE AND COMPETITIVE ANALYSIS

INDUSTRY STRUCTURE 31

TIERS OF COMPETITION 31

TABLE 5 INDUSTRY STRUCTURE--MAJOR COMPETITORS AND MARKETED PRODUCTS 31

TABLE 5 (CONTINUED) 32

MARKET CONCENTRATION AND PRICE SENSITIVITY 32

BARRIERS TO ENTRY 33

Market Saturation and Competitiveness 33

Sales and Marketing Capabilities 33

Drug Formulation and Delivery 34

Complex Regulatory and Drug Approval Process 35

NOTABLE MERGERS AND ACQUISITIONS 36

REGULATORY ASPECTS 36

REMOVAL OF CFC-PROPELLED DRUGS AS REQUIRED BY THE MONTREAL PROTOCOL ELIMINATED GENERIC COMPETITION FROM THE U.S. MARKET 36

PATIENT SAFETY ISSUES LED TO MORE STRINGENT LABELING REVISIONS AND GUIDES FOR ASTHMA AND COPD DRUGS 37

COMPETITIVE FACTORS 38

DELIVERY MODE AND CONVENIENCE 38

PRODUCT EFFICACY AND DOSAGE FREQUENCY 39

SAFETY PROFILE 39

COMBINATION DRUGS 40

PRICE 40

MARKETING AND SALES EFFECTIVENESS 41

MARKET CHALLENGES 41

TECHNICAL- AND MARKET-SPECIFIC EXPERTISE REQUIRED TO COMPETE IN THIS THERAPEUTIC AREA 41

THE COMPLEX DRUG DEVELOPMENT PROCESS 42

MARKET UNMET NEEDS 42

DISEASE-MODIFYING DRUGS 42

SUPERIOR EFFICACY DRUGS 43

IMPROVED SAFETY PROFILE DRUGS 43

IMPROVED DRUG DELIVERY MODALITIES 43

IMPROVED QUALITY OF LIFE FOR PATIENTS 44

MARKET TRENDS 44

TABLE 6 MARKET TRENDS IN THE ASTHMA/COPD MEDICATION MARKET 44

INCREASED PREVALENCE OF ASTHMA AND COPD IS EXPECTED TO DRIVE MARKET GROWTH GLOBALLY 45

ENHANCED PATIENT AWARENESS IS EXPECTED TO LEAD TO GREATER DIAGNOSIS AND TREATMENT RATES 45

NEW PRODUCT LAUNCHES WITH ENHANCED CONVENIENCE AND SAFETY PROFILES ARE EXPECTED TO EXPAND THE OVERALL MARKET 45

REMOVAL OF CFC-PROPELLED INHALERS FROM THE MARKET IS EXPECTED TO DRIVE MARKET GROWTH 46

CHANGES IN REIMBURSEMENT RATES AFFECT DRUG REVENUES 46

LOSS OF PATENT PROTECTION FOR MAJOR BLOCKBUSTER DRUGS IS EXPECTED TO SLOW THE OVERALL MARKET GROWTH 46

TOTAL MARKET REVENUES AND FORECAST 47

TOTAL MARKET REVENUES 47

TABLE 7 GLOBAL MARKET FOR ASTHMA AND COPD DRUGS, BY SEGMENT, 2008 ($ MILLIONS) 48

FIGURE 1 GLOBAL MARKET FOR ASTHMA AND COPD DRUGS, BY SEGMENT, 2008 ($ MILLIONS) 48

MARKET SHARES 49

TABLE 8 GLOBAL MARKET SHARES OF LEADING COMPANIES IN ASTHMA AND COPD MEDICATION, 2008 49

FIGURE 2 GLOBAL MARKET SHARES OF LEADING COMPANIES IN ASTHMA AND COPD MEDICATION, 2008 (%) 50

MARKET FORECAST 50

TABLE 9 GLOBAL MARKET FOR ASTHMA AND COPD DRUGS, THROUGH 2014 ($ MILLIONS) 51

FIGURE 3 GLOBAL MARKET FOR ASTHMA AND COPD DRUGS, 2007-2014 ($ MILLIONS) 52

Forecast Assumptions 52

Existing Drugs Revenue Increases 52

Patent Expirations of Major Drugs 53

Expected New Drug Launches 54

Expected New ... (Continued) 55

Expected New ... (Continued) 56

Chapter-6: MARKETS BY DRUG CLASSES

BRONCHODILATORS 57

OVERVIEW 57

MARKET REVENUES AND FORECAST 57

TABLE 10 MARKET SHARES OF LEADING COMPANIES SUPPLYING BRONCHODILATORS, 2008 58

FIGURE 4 MARKET SHARES OF LEADING COMPANIES SUPPLYING BRONCHODILATORS, 2008 (%) 58

TABLE 11 GLOBAL MARKET FOR BRONCHODILATORS, THROUGH 2014 ($ MILLIONS) 59

FIGURE 5 GLOBAL MARKET FOR BRONCHODILATORS, 2007-2014 ($ MILLIONS) 60

SHORT-ACTING BETA-2 AGONISTS 60

Overview 60

TABLE 12 SHORT-ACTING BETA-2 AGONISTS INDUSTRY STRUCTURE, 2009 61

Market Revenues and Forecast 61

TABLE 13 MARKET SHARES OF LEADING COMPANIES SUPPLYING SHORT-ACTING BETA-2 AGONISTS, 2008 (%) 62

FIGURE 6 MARKET SHARES OF LEADING COMPANIES SUPPLYING SHORT-ACTING BETA-2 AGONISTS, 2008 (%) 63

TABLE 14 GLOBAL MARKET FOR SHORT-ACTING BETA-2 AGONISTS, THROUGH 2014 ($ MILLIONS) 64

FIGURE 7 GLOBAL MARKET FOR SHORT-ACTING BETA-2 AGONISTS, 2007-2014 ($ MILLIONS) 64

Products Analysis 65

ProAir HFA 65

TABLE 15 PROAIR HFA ANALYSIS 66

Xopenex 66

TABLE 16 XOPENEX ANALYSIS 67

LONG-ACTING BETA-2 AGONISTS 68

Overview 68

TABLE 17 LONG-ACTING BETA-2 AGONISTS INDUSTRY STRUCTURE, 2009 68

Market Revenues and Forecast 68

Market Revenues and Forecast (Continued) 69

TABLE 18 MARKET SHARES OF LEADING COMPANIES SUPPLYING LONG-ACTING BETA-2 AGONISTS, 2008 70

FIGURE 8 MARKET SHARES OF LEADING COMPANIES SUPPLYING LONG-ACTING BETA-2 AGONISTS, 2008 (%) 70

TABLE 19 GLOBAL MARKET FOR LONG-ACTING BETA-2 AGONISTS, THROUGH 2014 ($ MILLIONS) 71

FIGURE 9 GLOBAL MARKET FOR LONG-ACTING BETA-2 AGONISTS, 2007-2014 ($ MILLIONS) 72

Products Analysis 72

Foradil 72

Foradil (Continued) 73

TABLE 20 FORADIL AEROLIZER ANALYSIS 74

Brovana 74

TABLE 21 BROVANA ANALYSIS 75

ANTICHOLINERGICS AND COMBINATION ANTICHOLINERGICS/SHORT-ACTING BETA-2 AGONISTS 75

Overview 75

TABLE 22 ANTICHOLINERGICS AND COMBINATION ANTICHOLINERGICS/SABA INDUSTRY STRUCTURE, 2009 76

Market Revenues and Forecast 76

TABLE 23 MARKET SHARES OF LEADING COMPANIES SUPPLYING ANTICHOLINERGICS, 2008 77

FIGURE 10 MARKET SHARES OF LEADING COMPANIES SUPPLYING ANTICHOLINERGICS, 2008 (%) 78

TABLE 24 GLOBAL MARKET FOR ANTICHOLINERGICS, THROUGH 2014 ($ MILLIONS) 79

FIGURE 11 GLOBAL MARKET FOR ANTICHOLINERGICS, 2007-2014 ($ MILLIONS) 79

Products Analysis 80

Spiriva 80

TABLE 25 SPIRIVA ANALYSIS 81

ANTI-INFLAMMATORY DRUGS 81

OVERVIEW 81

MARKET REVENUES AND FORECAST 81

TABLE 26 MARKET SHARES OF LEADING COMPANIES SUPPLYING ANTI-INFLAMMATORY DRUGS, 2008 82

FIGURE 12 MARKET SHARES OF LEADING COMPANIES SUPPLYING ANTI-INFLAMMATORY DRUGS, 2008 (%) 83

TABLE 27 GLOBAL MARKET FOR ANTI-INFLAMMATORY DRUGS, THROUGH 2014 ($ MILLIONS) 84

FIGURE 13 GLOBAL MARKET FOR ANTI-INFLAMMATORY DRUGS, THROUGH 2014 ($ MILLIONS) 84

INHALED CORTICOSTEROIDS 85

Overview 85

TABLE 28 INHALED CORTICOSTEROIDS INDUSTRY STRUCTURE, 2009 85

Market Revenues and Forecast 86

TABLE 29 MARKET SHARES OF LEADING COMPANIES SUPPLYING INHALED CORTICOSTEROIDS, 2008 (%) 87

FIGURE 14 MARKET SHARES OF LEADING COMPANIES SUPPLYING INHALED CORTICOSTEROIDS, 2008 (%) 87

TABLE 30 GLOBAL MARKET FOR INHALED CORTICOSTEROIDS, THROUGH 2014 ($ MILLIONS) 88

FIGURE 15 GLOBAL MARKET FOR INHALED CORTICOSTEROIDS, 2007-2014 ($ MILLIONS) 89

Products Analysis 89

Pulmicort 89

TABLE 31 PULMICORT ANALYSIS 90

Flovent/Flixotide 91

TABLE 32 FLOVENT ANALYSIS 92

LEUKOTRIENE MODIFIERS 92

Overview 92

TABLE 33 LONG-ACTING BETA-2 AGONISTS INDUSTRY STRUCTURE, 2009 93

Market Revenues and Forecast 93

TABLE 34 MARKET SHARES OF LEADING COMPANIES SUPPLYING LEUKOTRIENE MODIFIERS, 2008 (%) 94

FIGURE 16 MARKET SHARES OF LEADING COMPANIES SUPPLYING LEUKOTRIENE MODIFIERS, 2008 (%) 94

TABLE 35 GLOBAL MARKET FOR LEUKOTRIENE MODIFIERS, THROUGH 2014 ($ MILLIONS) 95

FIGURE 17 GLOBAL MARKET FOR LEUKOTRIENE MODIFIERS, THROUGH 2014 ($ MILLIONS) 96

Product Analysis 96

Singulair 96

TABLE 36 SINGULAIR ANALYSIS 97

BIOLOGICAL DRUGS 98

Overview 98

Market Revenues and Forecast 98

TABLE 37 GLOBAL MARKET FOR BIOLOGICAL DRUGS, THROUGH 2014 ($ MILLIONS) 99

FIGURE 18 GLOBAL MARKET FOR BIOLOGICAL DRUGS, 2007-2014 ($ MILLIONS) 99

Product Analysis 100

Xolair 100

TABLE 38 XOLAIR ANALYSIS 101

COMBINATION ICS/LABA DRUGS 101

OVERVIEW 101

TABLE 39 COMBINATION ICS/LABA INDUSTRY STRUCTURE, 2009 102

Market Revenues and Forecast 102

TABLE 40 MARKET SHARES OF LEADING COMPANIES SUPPLYING COMBINATION ICS/LABA, 2008 103

FIGURE 19 MARKET SHARES OF LEADING COMPANIES SUPPLYING COMBINATION ICS/LABA, 2008 (%) 103

Market Revenues and Forecast (Continued) 104

TABLE 41 GLOBAL MARKET FOR COMBINATION ICS/LABA DRUGS, THROUGH 2014 ($ MILLIONS) 105

FIGURE 20 GLOBAL MARKET FOR COMBINATION ICS/LABA DRUGS, 2007-2014 ($ MILLIONS) 105

Products Analysis 106

Advair/Seretide 106

TABLE 42 ADVAIR/SERETIDE ANALYSIS 107

Symbicort 107

Symbicort (Continued) 108

TABLE 43 SYMBICORT ANALYSIS 109

Chapter-7: MARKETS BY DISEASE

ASTHMA DRUGS MARKET 110

ASTHMA DRUGS 110

MARKET REVENUES 110

TABLE 44 GLOBAL MARKET FOR ASTHMA AND COPD PRESCRIPTION DRUGS BY DISEASE, 2008 ($ MILLIONS/%) 111

FIGURE 21 GLOBAL MARKET FOR ASTHMA AND COPD PRESCRIPTION DRUGS BY DISEASE, 2008 (%) 112

MARKET SHARES 112

TABLE 45 MARKET SHARES OF LEADING COMPANIES SUPPLYING THE ASTHMA DRUGS MARKET, 2008 113

FIGURE 22 MARKET SHARES OF LEADING COMPANIES SUPPLYING THE ASTHMA DRUGS MARKET, 2008 (%) 113

REVENUE FORECAST 114

New Branded Drugs Launches 114

Generic Drug Launches 115

TABLE 46 GLOBAL MARKET ASTHMA PRESCRIPTION DRUGS, THROUGH 2014 ($ MILLIONS) 116

FIGURE 23 GLOBAL MARKET ASTHMA PRESCRIPTION DRUGS, 2007-2014 ($ MILLIONS) 116

CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) DRUGS MARKET 117

COPD DRUGS 117

MARKET OVERVIEW 117

TABLE 47 GLOBAL MARKET FOR ASTHMA AND COPD PRESCRIPTION DRUGS BY DISEASE, 2008 ($ MILLIONS) 118

MARKET SHARES 118

TABLE 48 MARKET SHARES OF LEADING COMPANIES SUPPLYING COPD DRUGS, 2008 (%) 118

FIGURE 24 MARKET SHARES OF LEADING COMPANIES SUPPLYING COPD DRUGS, 2008 (%) 119

REVENUE FORECAST 119

New Branded Drug Launches 119

New Branded Drug Launches (Continued) 120

Generic Drug Launches 121

TABLE 49 GLOBAL MARKET FOR COPD PRESCRIPTION DRUGS, THROUGH 2014 ($ MILLIONS) 122

FIGURE 25 GLOBAL MARKET FOR COPD PRESCRIPTION DRUGS, 2007-2014 ($ MILLIONS) 122

Chapter-8: MARKETS BY GEOGRAPHICAL REGIONS

USA 123

MARKET OVERVIEW: PRODUCTS, SIGNIFICANT ASPECTS 123

Market Overview 123

TABLE 50 MARKET SHARES OF LEADING COMPANIES IN THE U.S. SUPPLYING ASTHMA AND COPD PRESCRIPTION DRUGS, 2008 (%) 123

FIGURE 26 MARKET SHARES OF LEADING COMPANIES IN THE U.S. SUPPLYING ASTHMA AND COPD PRESCRIPTION DRUGS, 2008 (%) 124

Products 124

Significant Aspects 125

REVENUE FORECAST 125

Revenue forecast (Continued) 126

TABLE 51 UNITED STATES MARKET FOR ASTHMA AND COPD PRESCRIPTION DRUGS, THROUGH 2014 ($ MILLIONS) 127

FIGURE 27 UNITED STATES MARKET FOR ASTHMA AND COPD PRESCRIPTION DRUGS, 2007-2014 ($ MILLIONS) 128

EUROPEAN UNION 128

MARKET OVERVIEW: PRODUCTS, SIGNIFICANT ASPECTS 128

Market Overview 128

TABLE 52 MARKET SHARES OF LEADING COMPANIES IN THE EUROPEAN UNION SUPPLYING ASTHMA AND COPD PRESCRIPTION DRUGS, 2008 (%) 129

FIGURE 28 MARKET SHARES OF LEADING COMPANIES IN THE EUROPEAN UNION SUPPLYING ASTHMA AND COPD PRESCRIPTION DRUGS, 2008 (%) 129

Products 130

Significant Aspects 130

REVENUE FORECAST 131

TABLE 53 EU MARKET FOR ASTHMA AND COPD PRESCRIPTION DRUGS, THROUGH 2014. ($ MILLIONS) 132

FIGURE 29 EU MARKET FOR ASTHMA AND COPD PRESCRIPTION DRUGS, 2007-2014 ($ MILLIONS) 133

REST OF THE WORLD MARKET 133

MARKET OVERVIEW: PRODUCTS, SIGNIFICANT ASPECTS 133

Market Overview 133

TABLE 54 MARKET SHARES OF LEADING COMPANIES SUPPLYING ASTHMA AND COPD PRESCRIPTION DRUGS TO ROW, 2008 (%) 134

FIGURE 30 MARKET SHARES OF LEADING COMPANIES SUPPLYING ASTHMA AND COPD PRESCRIPTION DRUGS TO ROW, 2008 (%) 134

Products 135

Significant Aspects 135

REVENUE FORECAST 135

TABLE 55 REST OF WORLD MARKET FOR ASTHMA AND COPD PRESCRIPTION DRUGS, THROUGH 2014 ($ MILLIONS) 136

FIGURE 31 REST OF WORLD MARKET FOR ASTHMA AND COPD PRESCRIPTION DRUGS, 2007-2014 ($ MILLIONS) 137

Chapter-9: PIPELINE REVIEW

PIPELINE OVERVIEW 138

BIOLOGICAL DRUGS 138

PDE-4 (PHOSPHODIESTERASE-4) INHIBITORS 138

CHEMOKINE RECEPTOR ANTAGONISTS 139

CRTH2 RECEPTOR ANTAGONISTS 139

KINASE INHIBITORS 140

BRONCHODILATORS 140

DRUGS FILED FOR REGULATORY APPROVAL 140

DRUGS IN PHASE III CLINICAL TRIALS 141

DRUGS IN PHASE II CLINICAL TRIALS 142

TABLE 56 LONG-ACTING BRONCHODILATORS PIPELINE, 2009 143

TABLE 56 (CONTINUED) 144

COMBINATION DRUGS OF INHALED CORTICOSTEROIDS AND LONG-ACTING BRONCHODILATORS 144

DRUGS FILED FOR REGULATORY APPROVAL 144

DRUGS IN PHASE III CLINICAL TRIALS 145

DRUGS IN PHASE II CLINICAL TRIALS 145

TABLE 57 COMBINATION ICS/LABA DRUGS PIPELINE, 2009 146

TABLE 57 (CONTINUED) 147

OTHER DRUG CLASSES 147

DRUGS FILED FOR REGULATORY APPROVAL 147

DRUGS IN PHASE II CLINICAL TRIALS 148

5-Lipoxygenase (5-LO) Inhibitors 148

Phosphodiesterase-4 (PDE-4) Inhibitors 148

CRTH2 Receptor Antagonists 148

Biological Drugs 149

Monoclonal Antibodies 149

Immunotherapy/Vaccines 149

RNA-silencing 150

Stem Cells Therapy 150

Other Mechanisms 151

TABLE 58 BIOLOGICAL DRUGS PIPELINE, 2009 152

TABLE 58 (CONTINUED) 153

TABLE 59 OTHER DRUG CLASSES PIPELINE, PHASE II, 2009 153

TABLE 59 (CONTINUED) 154

DRUGS IN PHASE I CLINICAL TRIALS 154

Drugs in Phase I Clinical Trials (Continued) 155

TABLE 60 OTHER DRUG CLASSES PIPELINE, PHASE I, 2009 156

Chapter-10: COMPANY PROFILES

ABBOTT LABORATORIES 157

AEROVANCE, INC. 157

ALKERMES, INC. 158

ALMIRALL, S.A. 158

ALTAIR THERAPEUTICS, INC. 159

AMGEN INC. 159

ARGENTA DISCOVERY, LTD. 160

ASTRAZENECA 161

ASTRAZENECA PHARMACEUTICALS, LP 161

BOEHRINGER INGELHEIM GMBH 162

BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 162

CYTOS BIOTECHNOLOGY AG 163

FOREST LABORATORIES, INC. 164

GENENTECH, INC. 164

GLAXO WELLCOME U.K., LTD. 165

GLAXOSMITHKLINE U.S. 165

ICAGEN, INC. 166

MEDICINOVA 167

MEDIMMUNE 167

MERCK & CO., INC. 168

NOVARTIS PHARMA 168

NOVARTIS CORPORATION 168

NOVARTIS PHARMACEUTICALS CORPORATION 168

NYCOMED INTERNATIONAL MANAGEMENT GMBH 169

OSIRIS THERAPEUTICS, INC. 170

PFIZER, INC. 171

SCHERING-PLOUGH CORPORATION 171

SEPRACOR, INC. 172

SKYEPHARMA PLC 173

TEVA PHARMACEUTICAL INDUSTRIES, LTD. 173

TEVA PHARMACEUTICALS USA 173

THERAVANCE 174

TOPIGEN PHARMACEUTICALS, INC. 175

VECTURA GROUP PLC 175

VECTURA GROUP PLC (CONTINUED) 176

To order this report:

Drug and Medication Industry: Global Markets for Asthma and COPD Drugs

More Market Research Report

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

Back to top

RELATED LINKS
http://www.reportlinker.com